시장보고서
상품코드
1994570

전두측두엽 치매 시장 보고서(2026년)

Frontotemporal Dementia Global Market Report 2026

발행일: | 리서치사: 구분자 The Business Research Company | 페이지 정보: 영문 250 Pages | 배송안내 : 2-10일 (영업일 기준)

    
    
    




■ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송일정은 문의해 주시기 바랍니다.

가격
PDF & Excel (Single User License) help
PDF & Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.
US $ 4,490 금액 안내 화살표 ₩ 6,686,000
PDF & Excel (Site License) help
PDF & Excel 보고서를 동일 기업의 동일 사업장 내의 모든 분이 이용할 수 있는 라이선스입니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.
US $ 6,490 금액 안내 화살표 ₩ 9,665,000
PDF & Excel (Enterprise License) help
PDF & Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 문서의 일부나 표는 Copy & Paste 가능합니다만 챕터 전체는 불가합니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF·Excel 이용 범위와 동일합니다.
US $ 8,490 금액 안내 화살표 ₩ 12,644,000
카드담기
※ 부가세 별도

전두측두엽 치매 시장 규모는 최근 몇 년간 크게 성장했습니다. 2025년 32억 5,000만 달러에서 2026년에는 35억 3,000만 달러에 이르고, CAGR 8.8%로 성장할 전망입니다. 지난 수년간의 성장 요인으로는 전두측두엽 치매에 대한 임상적 인식의 향상, 전문 신경과 클리닉의 확대, 신경영상 진단 기술의 보급, 의료진의 인식 제고 및 표준화된 진단 기준의 확립 등을 들 수 있습니다.

전두측두엽 치매 시장 규모는 향후 몇 년간 강력한 성장이 전망되고 있습니다. 2030년에는 49억 9,000만 달러에 이르고, CAGR은 9.0%를 나타낼 전망입니다. 예측 기간 동안의 성장 요인으로는 신경퇴행성 질환 연구에 대한 투자 확대, 정밀의료 접근법의 확산, 인지기능 평가를 위한 디지털 건강 도구의 확대, 질병 조절 요법에 대한 관심 증가, 간병인 지원 및 관리 프로그램 확대 등을 들 수 있습니다. 예측 기간의 주요 동향으로는 고급 신경영상 진단의 이용 확대, 유전자 검사 및 바이오마커 검사의 보급, 조기 및 정확한 질병 감별에 대한 관심 증가, 다직종 협력 진료 모델의 확대, 디지털 인지기능 평가 도구의 통합 강화 등을 들 수 있습니다.

정밀의료의 확대는 향후 전두측두엽 치매 시장의 성장을 견인할 것으로 예측됩니다. 정밀의학은 개인의 생물학적 특성, 유전적 요인, 생활습관에 따라 의료를 최적화하는 것을 말합니다. 유전체학 및 생명공학의 발전으로 질병 기전을 보다 정확하게 규명하고 표적 치료제를 개발할 수 있게 되어 환자 예후를 개선할 수 있게 됨에 따라 정밀의료의 도입이 진행되고 있습니다. 정밀의학은 유전자 검사 및 바이오마커 분석을 통해 보다 빠르고 정확한 진단을 가능하게 하고, 질병 진행에 관여하는 특정 분자 경로를 표적으로 하는 치료제 개발을 유도하여 전두측두엽 치매를 지원함으로써 치료 효과를 향상시키고 질병 진행을 늦추는 역할을 합니다. 예를 들어, 미국에 본사를 둔 비영리 단체인 개인화된 의학 연합(Personalized Medicine Coalition)에 따르면, 미국 식품의약국(FDA)은 2023년 희귀질환 환자를 위한 16개의 새로운 개인 맞춤형 치료법을 승인했습니다. 이는 암 및 기타 질환 영역의 치료제를 포함하여 2022년 승인 건수 6건에 비해 크게 증가한 수치입니다. 따라서 정밀의료의 보급 확대가 전두측두엽 치매 시장의 성장을 견인하고 있습니다.

전두측두엽 치매 시장에서 활동하는 주요 기업들은 질병의 진행을 늦추고 근본적인 병리학적 기전에 대처하기 위해 단일클론항체 치료와 같은 혁신적인 솔루션 개발에 집중하고 있습니다. 단일클론항체 치료는 체내의 특정 단백질이나 세포를 표적으로 하도록 설계된 실험실에서 제조된 항체를 사용하여 유해한 세포를 차단, 중화 또는 파괴하도록 표지하여 질병 치료를 돕는 치료 접근법을 말합니다. 예를 들어, 2024년 2월 미국 소재 임상 단계의 생명공학 기업 Alector Inc.는 영국 소재 바이오제약 기업 GSK Plc와 제휴하여 소토트릴린 수용체를 억제하고 뇌 내 프로그라눌린(PGRN) 수치를 증가시킴으로써 리소좀 기능 장애와 신경 퇴행을 개선하고, 프로그라눌린 유전자 변이로 인한 전두측두엽 치매(FTD-GRN)를 치료하기 위한 라투지네맙(AL001)에 대해 FDA로부터 혁신치료제 지정을 받았습니다. 임상 2상 시험에서 혈장 및 뇌척수액 내 PGRN이 2배 이상 안전하고 지속적으로 증가하며, 임상적 질병 진행 추이를 관찰할 수 있었습니다.

자주 묻는 질문

  • 전두측두엽 치매 시장 규모는 어떻게 변화하고 있나요?
  • 전두측두엽 치매 시장의 성장 요인은 무엇인가요?
  • 정밀의료가 전두측두엽 치매 시장에 미치는 영향은 무엇인가요?
  • 전두측두엽 치매 시장에서 주요 기업들은 어떤 혁신적인 솔루션을 개발하고 있나요?
  • 전두측두엽 치매 치료를 위한 최근의 임상 연구 결과는 어떤가요?

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 공급망 분석

제4장 세계 시장 동향과 전략

제5장 최종 이용 산업 시장 분석

제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오

제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석

제8장 TAM(Total Addressable Market) 규모

제9장 시장 세분화

제10장 지역별/국가별 분석

제11장 아시아태평양 시장

제12장 중국 시장

제13장 인도 시장

제14장 일본 시장

제15장 호주 시장

제16장 인도네시아 시장

제17장 한국 시장

제18장 대만 시장

제19장 동남아시아 시장

제20장 서유럽 시장

제21장 영국 시장

제22장 독일 시장

제23장 프랑스 시장

제24장 이탈리아 시장

제25장 스페인 시장

제26장 동유럽 시장

제27장 러시아 시장

제28장 북미 시장

제29장 미국 시장

제30장 캐나다 시장

제31장 남미 시장

제32장 브라질 시장

제33장 중동 시장

제34장 아프리카 시장

제35장 시장 규제 상황과 투자환경

제36장 경쟁 구도와 기업 개요

제37장 기타 주요 기업 및 혁신 기업

제38장 세계 시장 경쟁 벤치마킹과 대시보드

제39장 시장에서 주목 받는 신생 기업

제40장 주요 인수합병(M&A)

제41장 시장 잠재력이 높은 국가, 부문, 전략

제42장 부록

LSH 26.04.22

Frontotemporal dementia is a set of neurodegenerative conditions marked by progressive deterioration of the frontal and temporal lobes of the brain. It results in alterations in behavior, personality, language, and executive functions. The disorder generally worsens over time and significantly affects cognitive and social capabilities.

The primary disease types of frontotemporal dementia include behavioral variant frontotemporal dementia, primary progressive aphasia, and frontotemporal dementia with motor neuron disease. Behavioral variant frontotemporal dementia refers to a form of dementia characterized by significant changes in personality, behavior, and social conduct. These conditions are treated with drug classes such as cholinesterase inhibitors, N-methyl-D-aspartate receptor antagonists, antidepressants, and antipsychotics. The diagnostic methods include clinical evaluation, neuroimaging, and genetic testing. The treatment approaches include symptom management, medications, and speech and occupational therapy, and the end users are hospitals, specialty clinics, and long-term care facilities.

Tariffs are influencing the frontotemporal dementia market by increasing costs of imported diagnostic imaging equipment, genetic testing kits, laboratory reagents, and digital health technologies used in disease assessment and management. Healthcare systems in North America and Europe are most affected due to dependence on imported medical devices and diagnostics, while Asia-Pacific faces higher costs for specialized testing equipment. These tariffs are increasing diagnostic expenses and slowing technology upgrades. However, they are also encouraging regional manufacturing of diagnostic tools, localized laboratory services, and investment in digital-first dementia assessment solutions.

The frontotemporal dementia market research report is one of a series of new reports from The Business Research Company that provides frontotemporal dementia market statistics, including frontotemporal dementia industry global market size, regional shares, competitors with a frontotemporal dementia market share, detailed frontotemporal dementia market segments, market trends and opportunities, and any further data you may need to thrive in the frontotemporal dementia industry. This frontotemporal dementia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The frontotemporal dementia market size has grown strongly in recent years. It will grow from $3.25 billion in 2025 to $3.53 billion in 2026 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to improved clinical recognition of frontotemporal dementia, expansion of specialized neurology clinics, increased availability of neuroimaging technologies, rising awareness among healthcare professionals, development of standardized diagnostic criteria.

The frontotemporal dementia market size is expected to see strong growth in the next few years. It will grow to $4.99 billion in 2030 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period can be attributed to increasing investments in neurodegenerative disease research, rising adoption of precision medicine approaches, expansion of digital health tools for cognitive assessment, growing focus on disease-modifying therapies, increasing caregiver support and management programs. Major trends in the forecast period include increasing use of advanced neuroimaging diagnostics, rising adoption of genetic and biomarker testing, growing focus on early and accurate disease differentiation, expansion of multidisciplinary care models, enhanced integration of digital cognitive assessment tools.

The expansion of precision medicine is expected to propel the growth of the frontotemporal dementia market going forward. Precision medicine involves tailoring medical care based on an individual's biological characteristics, genetics, and lifestyle factors. Adoption of precision medicine is increasing due to advancements in genomics and biotechnology, which enable more accurate identification of disease mechanisms and the development of targeted therapies, leading to improved patient outcomes. Precision medicine supports frontotemporal dementia by enabling earlier and more accurate diagnosis through genetic testing and biomarker analysis, as well as guiding the development of therapies that target specific molecular pathways involved in disease progression, thereby improving treatment effectiveness and slowing disease advancement. For instance, according to the Personalized Medicine Coalition, a US-based non-profit organization, the US Food and Drug Administration approved 16 new personalized treatments for rare disease patients in 2023, compared to six approvals in 2022, including therapies for cancer and other disease areas. Therefore, the growing adoption of precision medicine is driving the growth of the frontotemporal dementia market.

Key companies operating in the frontotemporal dementia market are focusing on developing innovative solutions such as monoclonal antibody therapy to slow disease progression and address underlying pathological mechanisms. Monoclonal antibody therapy refers to a treatment approach that uses laboratory-made antibodies designed to target specific proteins or cells in the body, helping to treat diseases by blocking, neutralizing, or marking harmful cells for destruction. For example, in February 2024, Alector Inc., a US-based clinical-stage biotechnology company, partnered with GSK Plc., a UK-based biopharma company, and received FDA Breakthrough Therapy Designation for latozinemab (AL001), designed to treat frontotemporal dementia due to progranulin gene mutation (FTD-GRN) by inhibiting the sortilin receptor and elevating progranulin (PGRN) levels in the brain to address lysosomal dysfunction and neurodegeneration. Phase 2 trials demonstrated safe, sustained PGRN increases of over two-fold in plasma and cerebrospinal fluid, with observed trends toward slowing clinical disease progression.

In June 2024, Eli Lilly and Company, a US-based pharmaceutical company, entered into an exclusive license and research collaboration with QurAlis to develop splice-switching antisense oligonucleotides targeting UNC13A in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Through this partnership, the companies aim to develop and commercialize QRL-204 for FTD and ALS, while also collaborating on next-generation UNC13A-targeting therapies, expanding Lilly's neurodegeneration portfolio and accelerating precision medicine approaches for genetically defined forms of frontotemporal dementia. QurAlis, Inc. is a US-based clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, including FTD.

Major companies operating in the frontotemporal dementia market are Novartis AG, Eli Lilly and Company, Siemens Healthineers AG, Alector Inc., Denali Therapeutics Inc., Sangamo Therapeutics Inc., QurAlis Inc., TauRx Pharmaceuticals Ltd., AC Immune SA, AviadoBio Ltd., Passage Bio Inc., Muna Therapeutics Inc., Neurimmune Therapeutics Inc., Coya Therapeutics Inc., Aquinnah Pharmaceuticals Inc., Asceneuron SA, CAMP4 Therapeutics Inc., Libra Therapeutics Inc., SOLA Biosciences Inc., Transposon Therapeutics Inc.

North America was the largest region in the frontotemporal dementia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the frontotemporal dementia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the frontotemporal dementia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The frontotemporal dementia market includes revenues earned by entities through patient diagnosis and cognitive assessments, genetic and biomarker testing, neurological consultations, clinical management and treatment planning, and caregiver support and counseling services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Frontotemporal Dementia Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses frontotemporal dementia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on end user analysis.
  • Benchmark performance against key competitors based on market share, innovation, and brand strength.
  • Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
  • Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for frontotemporal dementia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The frontotemporal dementia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
  • The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
  • The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
  • The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
  • The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
  • The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

  • Markets Covered:1) By Disease Type: Behavioral Variant Frontotemporal Dementia (bvFTD); Primary Progressive Aphasia (PPA); Frontotemporal Dementia With Motor Neuron Disease (FTD-MND)
  • 2) By Drug Class: Cholinesterase Inhibitors; N-Methyl-D-Aspartate (NMDA) Receptor Antagonists; Antidepressants; Antipsychotics
  • 3) By Diagnostic Methods: Clinical Evaluation; Neuroimaging; Genetic Testing
  • 4) By Treatment Approach: Symptom Management; Medications; Speech And Occupational Therapy
  • 5) By End User: Hospitals; Specialty Clinics; Long-Term Care Facilities
  • Subsegments:
  • 1) By Behavioral Variant Frontotemporal Dementia (bvFTD): Disinhibited Type; Apathetic Type; Stereotypic Type; Hyperorality Type
  • 2) By Primary Progressive Aphasia (PPA): Nonfluent Variant; Semantic Variant; Logopenic Variant
  • 3) By Frontotemporal Dementia With Motor Neuron Disease (FTD-MND): Amyotrophic Lateral Sclerosis Associated; Progressive Muscular Atrophy Associated; Primary Lateral Sclerosis Associated
  • Companies Mentioned: Novartis AG; Eli Lilly and Company; Siemens Healthineers AG; Alector Inc.; Denali Therapeutics Inc.; Sangamo Therapeutics Inc.; QurAlis Inc.; TauRx Pharmaceuticals Ltd.; AC Immune SA; AviadoBio Ltd.; Passage Bio Inc.; Muna Therapeutics Inc.; Neurimmune Therapeutics Inc.; Coya Therapeutics Inc.; Aquinnah Pharmaceuticals Inc.; Asceneuron SA; CAMP4 Therapeutics Inc.; Libra Therapeutics Inc.; SOLA Biosciences Inc.; Transposon Therapeutics Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: Word, PDF or Interactive Report
  • + Excel Dashboard
  • Added Benefits
  • Bi-Annual Data Update
  • Customisation
  • Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

  • 1.1. Key Market Insights (2020-2035)
  • 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
  • 1.3. Major Factors Driving the Market
  • 1.4. Top Three Trends Shaping the Market

2. Frontotemporal Dementia Market Characteristics

  • 2.1. Market Definition & Scope
  • 2.2. Market Segmentations
  • 2.3. Overview of Key Products and Services
  • 2.4. Global Frontotemporal Dementia Market Attractiveness Scoring And Analysis
    • 2.4.1. Overview of Market Attractiveness Framework
    • 2.4.2. Quantitative Scoring Methodology
    • 2.4.3. Factor-Wise Evaluation
  • Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
    • 2.4.4. Market Attractiveness Scoring and Interpretation
    • 2.4.5. Strategic Implications and Recommendations

3. Frontotemporal Dementia Market Supply Chain Analysis

  • 3.1. Overview of the Supply Chain and Ecosystem
  • 3.2. List Of Key Raw Materials, Resources & Suppliers
  • 3.3. List Of Major Distributors and Channel Partners
  • 3.4. List Of Major End Users

4. Global Frontotemporal Dementia Market Trends And Strategies

  • 4.1. Key Technologies & Future Trends
    • 4.1.1 Biotechnology, Genomics & Precision Medicine
    • 4.1.2 Artificial Intelligence & Autonomous Intelligence
    • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
    • 4.1.4 Industry 4.0 & Intelligent Manufacturing
    • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
  • 4.2. Major Trends
    • 4.2.1 Increasing Use Of Advanced Neuroimaging Diagnostics
    • 4.2.2 Rising Adoption Of Genetic And Biomarker Testing
    • 4.2.3 Growing Focus On Early And Accurate Disease Differentiation
    • 4.2.4 Expansion Of Multidisciplinary Care Models
    • 4.2.5 Enhanced Integration Of Digital Cognitive Assessment Tools

5. Frontotemporal Dementia Market Analysis Of End Use Industries

  • 5.1 Hospitals
  • 5.2 Specialty Neurology Clinics
  • 5.3 Long-Term Care Facilities
  • 5.4 Diagnostic Centers
  • 5.5 Home Healthcare Providers

6. Frontotemporal Dementia Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Frontotemporal Dementia Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

  • 7.1. Global Frontotemporal Dementia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 7.2. Global Frontotemporal Dementia Market Size, Comparisons And Growth Rate Analysis
  • 7.3. Global Frontotemporal Dementia Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
  • 7.4. Global Frontotemporal Dementia Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Frontotemporal Dementia Total Addressable Market (TAM) Analysis for the Market

  • 8.1. Definition and Scope of Total Addressable Market (TAM)
  • 8.2. Methodology and Assumptions
  • 8.3. Global Total Addressable Market (TAM) Estimation
  • 8.4. TAM vs. Current Market Size Analysis
  • 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Frontotemporal Dementia Market Segmentation

  • 9.1. Global Frontotemporal Dementia Market, Segmentation By Disease Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Behavioral Variant Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia (PPA), Frontotemporal Dementia With Motor Neuron Disease (FTD-MND)
  • 9.2. Global Frontotemporal Dementia Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antidepressants, Antipsychotics
  • 9.3. Global Frontotemporal Dementia Market, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Clinical Evaluation, Neuroimaging, Genetic Testing
  • 9.4. Global Frontotemporal Dementia Market, Segmentation By Treatment Approach, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Symptom Management, Medications, Speech And Occupational Therapy
  • 9.5. Global Frontotemporal Dementia Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Hospitals, Specialty Clinics, Long-Term Care Facilities
  • 9.6. Global Frontotemporal Dementia Market, Sub-Segmentation Of Behavioral Variant Frontotemporal Dementia (bvFTD), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Disinhibited Type, Apathetic Type, Stereotypic Type, Hyperorality Type
  • 9.7. Global Frontotemporal Dementia Market, Sub-Segmentation Of Primary Progressive Aphasia (PPA), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Nonfluent Variant, Semantic Variant, Logopenic Variant
  • 9.8. Global Frontotemporal Dementia Market, Sub-Segmentation Of Frontotemporal Dementia With Motor Neuron Disease (FTD-MND), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • Amyotrophic Lateral Sclerosis Associated, Progressive Muscular Atrophy Associated, Primary Lateral Sclerosis Associated

10. Frontotemporal Dementia Market Regional And Country Analysis

  • 10.1. Global Frontotemporal Dementia Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
  • 10.2. Global Frontotemporal Dementia Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Frontotemporal Dementia Market

  • 11.1. Asia-Pacific Frontotemporal Dementia Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 11.2. Asia-Pacific Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Frontotemporal Dementia Market

  • 12.1. China Frontotemporal Dementia Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 12.2. China Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Frontotemporal Dementia Market

  • 13.1. India Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Frontotemporal Dementia Market

  • 14.1. Japan Frontotemporal Dementia Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 14.2. Japan Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Frontotemporal Dementia Market

  • 15.1. Australia Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Frontotemporal Dementia Market

  • 16.1. Indonesia Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Frontotemporal Dementia Market

  • 17.1. South Korea Frontotemporal Dementia Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 17.2. South Korea Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Frontotemporal Dementia Market

  • 18.1. Taiwan Frontotemporal Dementia Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 18.2. Taiwan Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Frontotemporal Dementia Market

  • 19.1. South East Asia Frontotemporal Dementia Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 19.2. South East Asia Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Frontotemporal Dementia Market

  • 20.1. Western Europe Frontotemporal Dementia Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 20.2. Western Europe Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Frontotemporal Dementia Market

  • 21.1. UK Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Frontotemporal Dementia Market

  • 22.1. Germany Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Frontotemporal Dementia Market

  • 23.1. France Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Frontotemporal Dementia Market

  • 24.1. Italy Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Frontotemporal Dementia Market

  • 25.1. Spain Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Frontotemporal Dementia Market

  • 26.1. Eastern Europe Frontotemporal Dementia Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 26.2. Eastern Europe Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Frontotemporal Dementia Market

  • 27.1. Russia Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Frontotemporal Dementia Market

  • 28.1. North America Frontotemporal Dementia Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 28.2. North America Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Frontotemporal Dementia Market

  • 29.1. USA Frontotemporal Dementia Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 29.2. USA Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Frontotemporal Dementia Market

  • 30.1. Canada Frontotemporal Dementia Market Overview
  • Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 30.2. Canada Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Frontotemporal Dementia Market

  • 31.1. South America Frontotemporal Dementia Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 31.2. South America Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Frontotemporal Dementia Market

  • 32.1. Brazil Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Frontotemporal Dementia Market

  • 33.1. Middle East Frontotemporal Dementia Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 33.2. Middle East Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Frontotemporal Dementia Market

  • 34.1. Africa Frontotemporal Dementia Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 34.2. Africa Frontotemporal Dementia Market, Segmentation By Disease Type, Segmentation By Drug Class, Segmentation By Diagnostic Methods, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Frontotemporal Dementia Market Regulatory and Investment Landscape

36. Frontotemporal Dementia Market Competitive Landscape And Company Profiles

  • 36.1. Frontotemporal Dementia Market Competitive Landscape And Market Share 2024
    • 36.1.1. Top 10 Companies (Ranked by revenue/share)
  • 36.2. Frontotemporal Dementia Market - Company Scoring Matrix
    • 36.2.1. Market Revenues
    • 36.2.2. Product Innovation Score
    • 36.2.3. Brand Recognition
  • 36.3. Frontotemporal Dementia Market Company Profiles
    • 36.3.1. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.2. Eli Lilly and Company Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.3. Siemens Healthineers AG Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.4. Alector Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 36.3.5. Denali Therapeutics Inc. Overview, Products and Services, Strategy and Financial Analysis

37. Frontotemporal Dementia Market Other Major And Innovative Companies

  • Sangamo Therapeutics Inc., QurAlis Inc., TauRx Pharmaceuticals Ltd., AC Immune SA, AviadoBio Ltd., Passage Bio Inc., Muna Therapeutics Inc., Neurimmune Therapeutics Inc., Coya Therapeutics Inc., Aquinnah Pharmaceuticals Inc., Asceneuron SA, CAMP4 Therapeutics Inc., Libra Therapeutics Inc., SOLA Biosciences Inc., Transposon Therapeutics Inc.

38. Global Frontotemporal Dementia Market Competitive Benchmarking And Dashboard

39. Upcoming Startups in the Market

40. Key Mergers And Acquisitions In The Frontotemporal Dementia Market

41. Frontotemporal Dementia Market High Potential Countries, Segments and Strategies

  • 41.1 Frontotemporal Dementia Market In 2030 - Countries Offering Most New Opportunities
  • 41.2 Frontotemporal Dementia Market In 2030 - Segments Offering Most New Opportunities
  • 41.3 Frontotemporal Dementia Market In 2030 - Growth Strategies
    • 41.3.1 Market Trend Based Strategies
    • 41.3.2 Competitor Strategies

42. Appendix

  • 42.1. Abbreviations
  • 42.2. Currencies
  • 42.3. Historic And Forecast Inflation Rates
  • 42.4. Research Inquiries
  • 42.5. The Business Research Company
  • 42.6. Copyright And Disclaimer
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제